Glucose-Cholesterol Interaction Magnifies Coronary Heart Disease Risk for Hypertensive Patients
暂无分享,去创建一个
[1] A. Cerami,et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.
[2] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[3] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[5] P. Hopkins,et al. A survey of 246 suggested coronary risk factors. , 1981, Atherosclerosis.
[6] H. Cohen,et al. Glucose interaction magnifies atherosclerotic risk from cholesterol. Findings from the PDAY Study. , 2004, Atherosclerosis.
[7] M. Alderman,et al. Diabetes and cardiovascular events in hypertensive patients. , 1999, Hypertension.
[8] D. Reed,et al. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. , 1986, The American journal of medicine.
[9] M. Alderman,et al. Detection and treatment of hypertension at the work site. , 1975, The New England journal of medicine.
[10] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[11] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[12] J. Neaton,et al. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. , 1985, Archives of internal medicine.
[13] M. Pagano,et al. Survival analysis. , 1996, Nutrition.
[14] M. Alderman,et al. History of Treatment for Depression: Risk Factor for Myocardial Infarction in Hypertensive Patients , 2001, Psychosomatic medicine.
[15] The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.
[16] S Greenland,et al. Concepts of interaction. , 1980, American journal of epidemiology.
[17] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[18] S. Soegondo. Atherogenic dyslipidemia and the metabolic syndrome. , 2005, Acta medica Indonesiana.
[19] C. Puglia,et al. Evaluation of oxidative stress in diabetic patients after supplementation with a standardised red orange extract. , 2002, Diabetes, nutrition & metabolism.
[20] W. Kannel,et al. A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.
[21] G. Renier,et al. Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose : role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[22] G. Sobal,et al. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. , 2000, Prostaglandins, leukotrienes, and essential fatty acids.
[23] A. Sharrett,et al. Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.
[24] Tomás Pantoja,et al. Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .
[25] Paul M. Ridker,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003 .
[26] W. L. Ooi,et al. Treatment-induced blood pressure reduction and the risk of myocardial infarction. , 1989, JAMA.
[27] M. Alderman,et al. High and low serum potassium associated with cardiovascular events in diuretic-treated patients , 2001, Journal of hypertension.
[28] S. Grundy. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. , 1998, The American journal of cardiology.
[29] L. Guize,et al. Impaired Fasting Glucose, Blood Pressure and Cardiovascular Disease Mortality , 2002, Hypertension.
[30] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[31] A. Catapano,et al. Low density lipoprotein oxidation, antioxidants, and atherosclerosis , 2000, Current opinion in cardiology.
[32] G. Davı̀,et al. Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.
[33] J. Yoshikawa,et al. Oxidative Stress in Leukocytes Is a Possible Link Between Blood Pressure, Blood Glucose, and C-Reacting Protein , 2002, Hypertension.